Nivolumab for the treatment of hepatocellular carcinoma.

This article reviews the concept of immunotherapy in liver cancer with focus on nivolumab. Expert commentary: Immunotherapy in hepatocellular carcinoma provides a new treatment option for patients in advanced stages besides sorafenib and other newly approved tyrosine kinase inhibitors. More data concerning effectivity and choosing the right patients for immunotherapy is warranted in the future. PMID: 30304963 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research